Sarepta Therapeutics Q4 Revenue Climbs 14% to $779M, Cash Tops $2.1B
Sarepta Therapeutics reported Q4 2025 revenue of $779 million, up 14% year-over-year, and full-year revenue of $2.8 billion, ending the period with $2.1 billion in cash and marketable securities. Management’s Q4 earnings call highlighted completion of enrollment for the Phase III micro-dystrophin gene therapy trial and implementation of cost-saving measures.
1. Q4 and Full-Year Financial Results
Sarepta Therapeutics closed Q4 2025 with $779 million in revenue, a 14% increase from Q4 2024, driving full-year revenue to $2.8 billion. The company maintained strong liquidity with $2.1 billion in cash and marketable securities as of December 31, 2025.
2. Earnings Call Highlights
During the Q4 earnings call, management emphasized execution of its cost-saving program, which is expected to reduce operating expenses by 10% in 2026. Leadership also reiterated its 2026 revenue guidance range of $3.1 billion to $3.3 billion and confirmed no new share issuances are planned.
3. Pipeline and Corporate Developments
Sarepta announced completion of enrollment in its pivotal Phase III trial of the micro-dystrophin gene therapy for Duchenne muscular dystrophy, with topline data anticipated mid-2026. The company also disclosed a new collaboration on next-generation exon-skipping therapies, expanding its rare disease pipeline.